Meet our team at the ASGCT: May 16-19, 2023 in Los Angeles, CA.
The event
The ASGCT conference will take place May 16-19 2023 at the Los Angeles Convention Center in Los Angeles, CA.
Our team
Meet our team during the event:
Stop by our booth #715 to meet our team during the ASGCT conference and learn more about our extended services to bring your cell and gene therapies to life… From process development up to commercial launch, Yposkesi is the full-service CDMO of choice, working by your side, to meet your timelines and budget.
Poster presentation, on the behalf of BioPhorum.
Current approaches and considerations for viral clearance in cell and gene therapy (CGT)
Wensheng Wang (Bayer Healthcare), Marian McKee (Eurofins BPT), James Berrie (Lonza) , Manjula Aysola and Kathy Remington (Merck KGaA), Robert Seymour (Pharmaron), Lu Wang (Spark Therapeutics), Johanna Kindermann (Takeda) and Brian Mullan (Yposkesi)
BioPhorum Cell and Gene Therapy is an industry-wide consortium that supports the quest for better and faster development of cell and gene therapies.The assurance of viral safety in cell and gene therapy (CGT) products poses a unique challenge as the viral vector is a key component of both in vivo and ex vivo gene therapies. Although viral clearance strategies for general biological drug manufacturing and vaccine production will be applicable to these products, there will be unique challenges and considerations for CGT modalities. BioPhorum CGT validation workstream have produced a publication which intends to indicate in a single location the major relevant existing guidance and advice on viral clearance for viral vectors with an emphasis on adeno-associated viral (AAV) vectors.
When?
The presentation of will be held during Friday Poster session, on May 19 from 12:00 to 14:00.
Poster ID is 1330.
Learn more about our newly launched Lentiviral Vector Manufacturing Platform: LentiSure™!
At the beginning of April 2023, Yposkesi launched its new Lentiviral Vector Manufacturing Platform, LentiSure.
LentiSure is providing the premium quality grade lentiviral vectors you need to assure your clinical development and commercial cell and gene therapy pipeline. LentiSure’s robust, scalable, and plug & play-optimized processes enable you to accelerate the time to market of your cell and gene therapies and facilitate better patient outcomes. You obtain a safe and effective product through LentiSure’s high productivity and established analytical methods. LentiSure is the choice for high titers, transduction efficiency, reliability, and accessing scalable production processes with optimized purification techniques.